Tarsus Pharmaceuticals, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Tarsus Pharmaceuticals, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Tarsus Pharmaceuticals, Inc. do? Business model and key facts
Get the full picture of Tarsus Pharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 323
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Stocks related to Tarsus Pharmaceuticals, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Tarsus Pharmaceuticals, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Tarsus Pharmaceuticals, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
